Search Results for "Skin"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Skin. Results 101 to 110 of 123 total matches.
Guselkumab (Tremfya) for Ulcerative Colitis
The Medical Letter on Drugs and Therapeutics • Mar 17, 2025 (Issue 1724)
fungal skin infections and herpes
simplex infections, have occurred in patients treated
with the drug ...
The interleukin (IL)-23 antagonist guselkumab
(Tremfya – Janssen Biotech) has now been approved
by the FDA for treatment of moderately to severely active ulcerative colitis (UC) in adults; it was
approved earlier for treatment of plaque psoriasis
and psoriatic arthritis. Guselkumab is the third IL-23
antagonist to be approved in the US for treatment of
UC; risankizumab (Skyrizi) and mirikizumab (Omvoh)
were approved earlier.
Med Lett Drugs Ther. 2025 Mar 17;67(1724):46-8 doi:10.58347/tml.2025.1724d | Show Introduction Hide Introduction
Drugs for Treatment and Prevention of Venous Thromboembolism
The Medical Letter on Drugs and Therapeutics • Jul 25, 2022 (Issue 1655)
Unfractionated heparin (UFH) Heparin-induced thrombocytopenia, skin
necrosis, urticaria, increased liver ...
Anticoagulants are the drugs of choice for treatment
and prevention of deep venous thrombosis (DVT) and
pulmonary embolism (PE), collectively referred to as
venous thromboembolism (VTE). US guidelines for
treatment of VTE were updated in 2020 and 2021.
Expanded Table: Some Biologic Drugs and JAK Inhibitors for Rheumatoid Arthritis (online only)
The Medical Letter on Drugs and Therapeutics • Nov 15, 2021 (Issue 1637)
can occur; cytopenias
are rare
Increased risk of serious
infections; tuberculin skin
testing ...
View Expanded Table: Some Biologic Drugs and JAK Inhibitors for Rheumatoid Arthritis
Tirzepatide (Mounjaro) for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • Jul 11, 2022 (Issue 1654)
receptor
agonists. Skin reactions and serious hypersensitivity
reactions such as anaphylaxis ...
The FDA has approved tirzepatide (Mounjaro –
Lilly), a peptide hormone with activity at both
glucose-dependent insulinotropic polypeptide
(GIP) and glucagon-like peptide-1 (GLP-1)
receptors, to improve glycemic control in adults
with type 2 diabetes. Tirzepatide, which is injected
subcutaneously once weekly, is the first dual GIP/GLP-1 receptor agonist to become available in the
US. Selective GIP receptor agonists are not available
in the US; GLP-1 receptor agonists have been
available for years.
Dupilumab (Dupixent) for Eosinophilic Esophagitis and Prurigo Nodularis
The Medical Letter on Drugs and Therapeutics • Feb 06, 2023 (Issue 1669)
and is associated with HIV infection.6
Standard Treatment – Skin hydration with regular
use of emollients ...
The FDA has approved the subcutaneously
injected interleukin (IL)-4 receptor alpha antagonist
dupilumab (Dupixent – Sanofi/Regeneron)
for treatment of eosinophilic esophagitis (EoE)
in patients ≥12 years old who weigh ≥40 kg and
treatment of prurigo nodularis in adults. Dupilumab
is the first drug to be approved in the US for each
of these indications. It is also FDA-approved for
treatment of atopic dermatitis, asthma, and chronic
rhinosinusitis with nasal polyposis.
Med Lett Drugs Ther. 2023 Feb 6;65(1669):18-20 doi:10.58347/tml.2023.1669b | Show Introduction Hide Introduction
Comparison Table: Some Drugs for Gout (online only)
The Medical Letter on Drugs and Therapeutics • Oct 30, 2023 (Issue 1688)
of
cyclosporine
Can prolong the half-life of
chlorpropamide
May increase frequency of skin rash in
patients ...
View the Comparison Table: Some Drugs for Gout
Med Lett Drugs Ther. 2023 Oct 30;65(1688):e176-9 doi:10.58347/tml.2023.1688c | Show Introduction Hide Introduction
Drugs for Open-Angle Glaucoma
The Medical Letter on Drugs and Therapeutics • Apr 28, 2025 (Issue 1727)
, and an increase
in periorbital skin pigmentation. PGAs may also cause
local irritation, itching, dryness ...
Glaucoma is a progressive optic neuropathy
associated with increased intraocular pressure
(IOP; normal range 8-22 mm Hg), which is the only
disease-related factor that can be modified. Topical
drugs that lower IOP are the first line of treatment for
open-angle glaucoma.
Med Lett Drugs Ther. 2025 Apr 28;67(1727):65-8 doi:10.58347/tml.2025.1727a | Show Introduction Hide Introduction
Comparison Table: Inhaled Drugs for Treatment of COPD (online only)
The Medical Letter on Drugs and Therapeutics • Sep 02, 2024 (Issue 1710)
and dysphonia
▶ Systemic absorption has been associated with skin bruising,
cataracts, reduced bone mineral ...
View the Comparison Table: Inhaled Drugs for Treatment of COPD
Med Lett Drugs Ther. 2024 Sep 2;66(1710):e143-7 doi:10.58347/tml.2024.1710b | Show Introduction Hide Introduction
Choice of Contraceptives
The Medical Letter on Drugs and Therapeutics • May 15, 2023 (Issue 1676)
with oral contraceptives.
Skin irritation at the application site can occur and
may lead ...
Intrauterine devices (IUDs) and the etonogestrel
implant are the most effective reversible contraceptive
methods available. Hormonal oral contraceptives,
patches, rings, and injectables are also effective in
preventing pregnancy. When used alone, barrier and
behavioral methods generally have higher failure
rates than other methods (see Table 1). Selection of
a contraceptive method is usually based on patient-specific factors and personal preference
Med Lett Drugs Ther. 2023 May 15;65(1676):73-80 doi:10.58347/tml.2023.1676a | Show Introduction Hide Introduction
Drugs for Age-Related Macular Degeneration
The Medical Letter on Drugs and Therapeutics • Jan 06, 2025 (Issue 1719)
during the infusion. The skin and eyes of
patients who receive verteporfin may be sensitive to
sunlight ...
Age-related macular degeneration (AMD) has two
major forms: dry or non-neovascular (~90% of
patients) and wet or neovascular (~10% of patients).
Med Lett Drugs Ther. 2025 Jan 6;67(1719):1-5 doi:10.58347/tml.2025.1719a | Show Introduction Hide Introduction